Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Typhoid Fever - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Typhoid Fever - Pipeline Review, H1 2016', provides an overview of the Typhoid Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Typhoid Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Typhoid Fever - The report reviews pipeline therapeutics for Typhoid Fever by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Typhoid Fever therapeutics and enlists all their major and minor projects - The report assesses Typhoid Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Typhoid Fever Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Typhoid Fever - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Typhoid Fever pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Typhoid Fever Overview 7 Therapeutics Development 8 Pipeline Products for Typhoid Fever - Overview 8 Pipeline Products for Typhoid Fever - Comparative Analysis 9 Typhoid Fever - Therapeutics under Development by Companies 10 Typhoid Fever - Therapeutics under Investigation by Universities/Institutes 11 Typhoid Fever - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Typhoid Fever - Products under Development by Companies 16 Typhoid Fever - Products under Investigation by Universities/Institutes 17 Typhoid Fever - Companies Involved in Therapeutics Development 18 GlaxoSmithKline Plc 18 Nanotherapeutics, Inc. 19 Prokarium Limited 20 Protein Potential, LLC 21 Sanofi 22 Shantha Biotechnics Limited 23 SK Chemicals Co., Ltd. 24 Zydus Cadila Healthcare Limited 25 Typhoid Fever - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Target 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 (paratyphoid (bivalent) + typhoid) vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 (paratyphoid + typhoid) vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 (shigella + typhoid) vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 (Streptococcal pneumonia + typhoid) vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Typhella - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Typhetec - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 typhoid vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 typhoid vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 typhoid vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 ViCRM-197 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Typhoid Fever - Recent Pipeline Updates 46 Typhoid Fever - Dormant Projects 47 Typhoid Fever - Discontinued Products 48 Typhoid Fever - Product Development Milestones 49 Featured News & Press Releases 49 Mar 11, 2013: Prokarium and University Of Birmingham Receive £0.4m Grant To Develop Next Generation Vaccines 49 Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine 49 Jun 23, 2011: Sanofi Pasteur's Typhim VI Receives Prequalification from World Health Organization 49 Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate 50 Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine 50 Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine 51 Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results in Phase II Clinical Study 51 Nov 29, 1994: Food and Drug Administration Grants License For A New Typhoid Fever Vaccine 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development for Typhoid Fever, H1 2016 8 Number of Products under Development for Typhoid Fever - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Comparative Analysis by Unknown Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H1 2016 18 Typhoid Fever - Pipeline by Nanotherapeutics, Inc., H1 2016 19 Typhoid Fever - Pipeline by Prokarium Limited, H1 2016 20 Typhoid Fever - Pipeline by Protein Potential, LLC, H1 2016 21 Typhoid Fever - Pipeline by Sanofi, H1 2016 22 Typhoid Fever - Pipeline by Shantha Biotechnics Limited, H1 2016 23 Typhoid Fever - Pipeline by SK Chemicals Co., Ltd., H1 2016 24 Typhoid Fever - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Assessment by Combination Products, H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Route of Administration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 33 Typhoid Fever Therapeutics - Recent Pipeline Updates, H1 2016 46 Typhoid Fever - Dormant Projects, H1 2016 47 Typhoid Fever - Discontinued Products, H1 2016 48
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.